Download MendeleyPharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.
Burgey, C.S., Robinson, K.A., Lyle, T.A., Nantermet, P.G., Selnick, H.G., Isaacs, R.C., Lewis, S.D., Lucas, B.J., Krueger, J.A., Singh, R., Miller-Stein, C., White, R.B., Wong, B., Lyle, E.A., Stranieri, M.T., Cook, J.J., McMasters, D.R., Pellicore, J.M., Pal, S., Wallace, A.A., Clayton, F.C., Bohn, D., Welsh, D.C., Lynch, J.J., Yan, Y., Chen, Z., Kuo, L., Gardell, S.J., Shafer, J.A., Vacca, J.P.(2003) Bioorg Med Chem Lett 13: 1353-1357
- PubMed: 12657281
- DOI: https://doi.org/10.1016/s0960-894x(03)00099-4
- Primary Citation of Related Structures:
1MUE - PubMed Abstract:
In this manuscript we demonstrate that a modification principally directed toward the improvement of the aqueous solubility (i.e., introduction a P3 pyridine N-oxide) of the previous lead compound afforded a new series of potent orally bioavailable P1 N-benzylamide thrombin inhibitors. An expedited investigation of the P1 SAR with respect to oral bioavailability, plasma half-life, and human liver microsome stability revealed 5 as the best candidate for advanced evaluation.
Organizational Affiliation:
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. christopher_urgey@merck.com
